In a landscape where over 50% of pharmaceuticals distributed in the US are manufactured overseas, the fragility of the drug supply chain has become a pressing concern for national health security, prompting urgent action. Imagine a scenario where a global crisis disrupts access to essential
In a landscape where economic volatility often shakes investor confidence, Becton Dickinson (BDX) has emerged as a standout performer, recently revising its full-year earnings outlook upward with an adjusted diluted EPS guidance of $14.30 to $14.45, reflecting a robust 9.4% growth at the midpoint.
The pharmaceutical industry stands on the brink of a technological revolution with the recent release of the Good Automated Manufacturing Practice (GAMP) Artificial Intelligence Guide by the International Society for Pharmaceutical Engineering (ISPE). As pharmaceutical companies increasingly turn
The cell and gene therapy (CGT) market is undergoing rapid expansion as it transforms healthcare with innovative treatments for previously incurable diseases. This exhilarating growth is projected to reach $28 billion by the year 2030, marking a significant milestone. Experts attribute this
With a wealth of experience in biopharma and a keen eye for technological advancement, Ivan Kairatov stands at the forefront of innovation in the industry. Today, he shares his insights on the FDA's recent decision to publish complete response letters (CRLs), a move designed to enhance transparency
The One Big Beautiful Bill Act, signed into law by President Donald Trump, has polarized opinions in the healthcare community due to its sweeping changes. Central to the apprehension is its significant reduction in Medicaid spending and the eradication of Affordable Care Act subsidies. These
